ReviewCost effectiveness and resource allocation : C/E2021

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.

Zoltán Kaló et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.